HC Wainwright Predicts Co-Diagnostics Q1 Earnings

Co-Diagnostics, Inc. (NASDAQ:CODX) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Co-Diagnostics in a report released on Monday, May 12th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.34) EPS.

Co-Diagnostics (NASDAQ:CODX) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.09. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.38 million. Co-Diagnostics had a negative return on equity of 54.94% and a negative net margin of 563.93%.

CODX has been the subject of a number of other reports. D Boral Capital upgraded Co-Diagnostics to a “strong-buy” rating in a report on Monday, April 28th. D. Boral Capital initiated coverage on Co-Diagnostics in a report on Monday, April 28th. They set a “buy” rating and a $10.00 price target for the company.

Co-Diagnostics Stock Down 4.9%

NASDAQ CODX opened at $0.34 on Tuesday. The company has a market capitalization of $11.57 million, a price-to-earnings ratio of -0.25 and a beta of 0.84. Co-Diagnostics has a twelve month low of $0.28 and a twelve month high of $2.23. The stock has a fifty day simple moving average of $0.38 and a 200 day simple moving average of $0.68.

Institutional Trading of Co-Diagnostics

Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Co-Diagnostics during the 3rd quarter worth about $55,000. Thompson Davis & CO. Inc. grew its holdings in Co-Diagnostics by 37.8% during the 4th quarter. Thompson Davis & CO. Inc. now owns 57,200 shares of the company’s stock worth $43,000 after acquiring an additional 15,700 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Co-Diagnostics by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 345,511 shares of the company’s stock worth $259,000 after acquiring an additional 24,236 shares during the period. 14.99% of the stock is currently owned by institutional investors and hedge funds.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.